deferoxamine has been researched along with adamantane in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Codd, R; Groebler, LK; Kalinowski, DS; Liu, J; Obando, D; Richardson, DR; Schipanski, LG; Witting, PK | 1 |
| Codd, R; Crouch, PJ; Ganio, G; Liddell, JR; Liu, J; Mok, SS; Obando, D; Volitakis, I; White, AR | 1 |
2 other study(ies) available for deferoxamine and adamantane
| Article | Year |
|---|---|
Conjugates of desferrioxamine B (DFOB) with derivatives of adamantane or with orally available chelators as potential agents for treating iron overload.
Topics: Adamantane; Administration, Oral; Animals; Binding Sites; Carboxylic Acids; Cell Proliferation; Cells, Cultured; Chelating Agents; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Deferoxamine; Dogs; Ferric Compounds; Humans; Inhibitory Concentration 50; Iron; Iron Chelating Agents; Iron Overload; Kidney; Models, Molecular; Molecular Structure; Neuroectodermal Tumors, Primitive, Peripheral; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Transferrin | 2010 |
Lipophilic adamantyl- or deferasirox-based conjugates of desferrioxamine B have enhanced neuroprotective capacity: implications for Parkinson disease.
Topics: Adamantane; Animals; Astrocytes; Benzoates; Cells, Cultured; Deferasirox; Deferoxamine; Dopaminergic Neurons; Humans; Hydrogen Peroxide; Iron Chelating Agents; Mice; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Permeability; Substantia Nigra; Triazoles | 2013 |